Major – Recall of Losartan
Major ? Recall of Losartan
? On January 10, 2019, Major announced a voluntary recall of one lot of losartan tablets due to the detection of trace amounts of an unexpected impurity, identified as N-nitrosodiethylamine (NDEA), found in an active pharmaceutical ingredient (API) manufactured by Hetero Labs.
? NDEA is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer classification.
-- Refer to the FDA site for updates regarding angiotensin II receptor blocker recalls.
? The recalled product is listed below:
Product Description Losartan 50 mg unit dose tablets
NDC# 0904-6390-61
Lot# (Expiration Date) R-00474 (7/2019)
? Losartan tablets are used for the treatment of hypertension (HTN); to reduce the risk of stroke in patients with HTN and left ventricular hypertrophy; and for the treatment of diabetic nephropathy with
an elevated serum creatinine and proteinuria (urinary albumin to creatinine ratio 300 mg/g) in patients with type 2 diabetes and a history of HTN.
? Patients should contact their pharmacist or physician who can advise them about an alternative treatment prior to returning their medication. Patients who are on losartan should continue taking their medication, as the risk of harm to a patient's health may be higher if the treatment is stopped immediately without any alternative treatment.
? Patients should contact their healthcare provider if they have experienced any problems that may be related to using the recalled losartan.
? Anyone with an existing inventory of the recalled product should stop use and distribution, and quarantine the product immediately.
? For more information regarding this recall, contact Torrent (manufacturer for Major) at 1-800-9129561 or Stericycle at 1-877-220-4728 for general questions regarding return of the product. For all other questions, contact Major at 1-800-616-2471.
OptumRx? specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum? company -- a leading provider of integrated health services. Learn more at . All Optum? trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.
This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx. RxNews? is published by the OptumRx Clinical Services Department.
?2019 Optum, Inc. All rights reserved.
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- losarta 50 losarta 50 mg losartan potassium tablets
- camber pharmaceuticals recall of losartan
- important losartan recall notice
- recall of losartan by major optumrx
- recall of losartan by avkare effective date april 23 2019
- losartan recall medsask
- drug recall list blue cross blue shield of michigan
- losartan potassium tablets may 3 2019 acid nmba impurity
- major recall of losartan
Related searches
- recall on losartan 2018 fda
- what lots of losartan are recalled
- list of losartan recall 2019
- recall on losartan 2019
- complete list of losartan recalls
- picture of losartan pill
- images of losartan potassium
- side effects of losartan 100 mg tablet
- picture of losartan 100
- picture of losartan pills
- picture of losartan 50 mg
- side effects of losartan 50 mg tab